These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 3909342

  • 1. Clinical experience with aztreonam in Germany and Austria.
    Stille W, Gillissen J.
    Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F, Douchamps J, Freschi E, Thys JP, Nève P, Herchuelz A.
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN, Heel RC.
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical studies of aztreonam in Japan.
    Hara K, Kobayashi H, Nishiura T, Yura J, Saito A.
    Rev Infect Dis; 1985 Feb; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [Abstract] [Full Text] [Related]

  • 9. The clinical use of aztreonam.
    Schönwald S, Schoss-Vidensek Z, Car V, Krznar B.
    Chemotherapy; 1989 Feb; 35 Suppl 1():45-8. PubMed ID: 2731450
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A, Steru D, Rosset MA, Carbon C.
    Rev Infect Dis; 1991 Feb; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
    Naber KG, Dette GA, Kees F, Knothe H, Grobecker H.
    J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM, Phillips HL, Hall HJ.
    Rev Infect Dis; 1985 Apr; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [Abstract] [Full Text] [Related]

  • 20. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden.
    Norrby SR.
    Rev Infect Dis; 1985 Apr; 7 Suppl 4():S836-9. PubMed ID: 2934788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.